

Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/G413B308B091EN.html>

Date: June 2022

Pages: 636

Price: US\$ 2,500.00 (Single User License)

ID: G413B308B091EN

Abstracts

Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) – Drugs In Development, 2022, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD) – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 11, 31, 28, 4, 63, 11 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 13 and 2 molecules, respectively.

Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology).

The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Graft Versus Host Disease (GVHD) – Overview
- Graft Versus Host Disease (GVHD) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Graft Versus Host Disease (GVHD) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Graft Versus Host Disease (GVHD) – Companies Involved in Therapeutics Development
- Graft Versus Host Disease (GVHD) – Drug Profiles
- Graft Versus Host Disease (GVHD) – Dormant Projects
- Graft Versus Host Disease (GVHD) – Discontinued Products
- Graft Versus Host Disease (GVHD) – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Graft Versus Host Disease (GVHD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Graft Versus Host Disease (GVHD) – Pipeline by 9 Meters Biopharma Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Abbisko Cayman Limited, 2022

Graft Versus Host Disease (GVHD) – Pipeline by AbbVie Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Accro BioScience (Suzhou) Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Actitrex GmbH, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Adienne Pharma & Biotech SA, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Alphamab Oncology, 2022

Graft Versus Host Disease (GVHD) – Pipeline by AltruBio Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Amcyte Pharma Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Amgen Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by AnaMar AB, 2022

Graft Versus Host Disease (GVHD) – Pipeline by AnaptysBio Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by ASC Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by AstraZeneca Plc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Athos Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Autolus Therapeutics Plc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Avalon GloboCare Corp, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Bellicum Pharmaceuticals Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Biocon Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Biogen Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by BioIncept LLC, 2022

Graft Versus Host Disease (GVHD) – Pipeline by BlueRock Therapeutics LLC, 2022

Graft Versus Host Disease (GVHD) – Pipeline by BlueSphere Bio Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Boryung ViGenCell Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Bristol-Myers Squibb Co, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Capricor Therapeutics Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Collective BioTherapy Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Cellenkos Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Cellestia Biotech AG, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Cellix Bio Pvt Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by CELLnLIFE Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Celltrion Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Cellvation Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by CheckPoint Immunology Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Claritas Pharmaceuticals Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Clinigen Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Connext Co Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Corvus Pharmaceuticals Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by CSL Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by CTI BioPharma Corp, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Cue Biopharma Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Cynata Therapeutics Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Cytopeutics Pte Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Dianomi Therapeutics Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Dualogics Corp, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Educell doo, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Eli Lilly and Co, 2022
Graft Versus Host Disease (GVHD) – Pipeline by enGene Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Equillium Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by EV Therapeutics Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Evive Biotech, 2022
Graft Versus Host Disease (GVHD) – Pipeline by ExCellThera Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Fate Therapeutics Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Forte Biosciences Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Genentech USA Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Glia LLC, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Good T Cells Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Grifols SA, 2022
Graft Versus Host Disease (GVHD) – Pipeline by GSK plc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Humanigen Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by iCELL Biotechnology Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Implacate Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Immune Modulation Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by ImmuneTarget Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Imstem Biotechnology Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Incyte Corp, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Inmagene Biopharmaceuticals Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Jazz Pharmaceuticals Plc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by JN Biosciences LLC, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Kadmon Holdings Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Kamada Pharmaceuticals, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Kiniksa Pharmaceuticals Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Kymab Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by MaaT Pharma, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Machavert Pharmaceuticals LLC, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Magenta Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Mallinckrodt Plc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Medexus Pharmaceuticals Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Medicenna Therapeutics Corp, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Mediolanum farmaceutici SpA, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Medsenic SAS, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Merck & Co Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Mereo Biopharma Group Plc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Mesoblast Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Millennium Pharmaceuticals Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by MiNK Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by MitolImmune Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Moderna Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by NapaJen Pharma Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Neoleukin Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Neovii Pharmaceuticals AG, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Nurix Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by OncoC4 Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Orca Biosystems Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by OSE Immunotherapeutics SA, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Ossium Health Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Panorama Researchama Research, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Pfizer Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Platinum Biotech (Beijing) Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Pluristem Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Precision Biosciences Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Rebus Holdings Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by REGiMMUNE Corp, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Rheos Medicines Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Sanofi, 2022

Graft Versus Host Disease (GVHD) – Pipeline by SCM lifescience Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Seagen Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Secura Bio Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Seres Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Sino Biopharmaceutical Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Sorrento Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by STERO Biotechs Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by StingInn LLC, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Suzhou Regend Therapeutics Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Syndax Pharmaceuticals Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Synthetic Biologics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Targazyme Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by TCF GmbH, 2022

Graft Versus Host Disease (GVHD) – Pipeline by TCR2 Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by TeralImmune Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Tianjin Angsai Cell Genetic Engineering Co Ltd, 2022

Graft Versus Host Disease (GVHD) – Pipeline by TreeFrog Therapeutics SAS, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Triursus Therapeutics Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by United BioPharma Inc, 2022

Graft Versus Host Disease (GVHD) – Pipeline by Vault Pharma Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by VectivBio Holding AG, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Vedanta Biosciences Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Viracta Therapeutics Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Visterra Inc, 2022
Graft Versus Host Disease (GVHD) – Pipeline by VITRAC Therapeutics LLC, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Xbiome Co Ltd, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Xenikos BV, 2022
Graft Versus Host Disease (GVHD) – Pipeline by Xenothera SAS, 2022
Graft Versus Host Disease (GVHD) – Dormant Projects, 2022
Graft Versus Host Disease (GVHD) – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Graft Versus Host Disease (GVHD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G413B308B091EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G413B308B091EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

